Two Clocks, One Stock: Diginex Battles Nasdaq Compliance and Resulticks Deadline

Diginex stock sits at $1.04, barely above Nasdaq's $1 minimum, with a June 12 deadline to close a transformative $150M revenue acquisition or face delisting by September 21.

The calendar at Diginex is marked with two red circles — and both are closing in fast. One deadline threatens the company’s listing on the Nasdaq; the other will determine whether it can pull off a deal that would transform its revenue base overnight. Meanwhile, the stock has lost a third of its value in the past month, closing Friday at $1.04.

Diginex received a formal warning from the Nasdaq in March after its share price closed below $1.00 for 30 consecutive trading days, violating Listing Rule 5550(a)(2). Management responded with a 1-for-8 reverse stock split in late April, mechanically lifting the price. The effect was short-lived. With a weekly loss of 28% and a 30-day decline of roughly 33%, the stock now sits barely above the delisting threshold. The company has until September 21 to regain and maintain compliance — or risk ejection from the exchange.

That Nasdaq clock is ticking alongside a separate, more immediate countdown. Diginex’s proposed acquisition of Resulticks Global Companies has been extended twice, with the latest long-stop date set for June 12. The deal, originally slated to close by late April, would bring in roughly $150 million in annual revenue and as much as $50 million in EBITDA. For context, Diginex itself generated only $3.6 million in revenue over the trailing twelve months and carries a market capitalization of about $34 million. The transaction would effectively transform the company from a niche ESG-data provider into a broader data and customer-engagement platform.

Management has been candid that closing is not guaranteed. Investors are clearly pricing in that uncertainty. The relative strength index sits at 30.4, signaling oversold territory, while annualized 30-day volatility has surged past 156% — technical markers of acute stress.

On the product side, Diginex has not been idle. On June 4, it launched Risk-to-Remedy, an end-to-end supply-chain due diligence platform that bundles transparency, risk assessment, remediation processes and regulatory reporting. The system rests on three modules: LUMEN for supply-chain risk screening, APPRISE for direct worker engagement, and expertise from The Remedy Project for grievance mechanisms. The offering targets tightening regulations such as Germany’s Lieferkettensorgfaltspflichtengesetz, the EU Corporate Sustainability Due Diligence Directive and the EU Forced Labour Regulation.

Diginex also points to operational improvements at its ESG data subsidiary, Matter, which counts institutions with $20 trillion in combined assets under management among its clients. The unit increased its automation rate for extracting carbon data from 25% to 80%. The broader strategy is to bundle Plan A, Matter, The Remedy Project and Diginex itself under a single technology umbrella.

The company has sized the supply-chain due diligence market at $3.8 billion in 2025, projecting it will reach $9.6 billion by 2034. Those figures come from its own communications and describe the addressable opportunity rather than actual revenue. Specific customer numbers or a timeline for further product expansions have not been disclosed.

For now, the market is looking past the product narrative and straight at the June 12 deadline. If the Resulticks deal falls through, Diginex loses the growth catalyst that might justify the current valuation — and the Nasdaq’s September 21 deadline will keep the pressure on. Two clocks, one stock, and a lot riding on the next few weeks.